Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

about

CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.Diagnosis and treatment of CD20 negative B cell lymphomas.De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge.

P2860

Q34460823-48F1839D-CBE9-4AF5-B589-9E57A1D42E6D Q39132786-3ED6DC72-10E4-4B34-9743-DD20B2C7B793 Q41923473-629A01FB-6675-441E-A67B-00E04DE774BB

P2860

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

Item

http://www.wikidata.org/entity/Q58919516

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2013

@uk

name

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

@en

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

@nl

type

Item

label

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

@en

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

@nl

prefLabel

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

@en

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

@nl

P1476

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

@en

P2093

Osvaldo Padilla

http://www.w3.org/2001/XMLSchema#string

Sumit Gaur

http://www.w3.org/2001/XMLSchema#string

Zeina Nahleh

http://www.w3.org/2001/XMLSchema#string

P2860

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective.

Plasmablastic lymphoma and related disorders.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/290585

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

about

P2860

P2860

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577